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There are at least 100 different autoimmune diseases 
that can affect any organ of the body. In the USA, it is 
estimated that autoimmune diseases affect between 5% 
and 8% of the population (14.7–23.5 million people), but 
individual autoimmune diseases like Addison’s disease, 
autoimmune neuropathies and ACNA vasculitis can cer-
tainly be classified as rare (affecting less than 200,000 
people [USA] or fewer than 1 in 2000 of the population 
[Europe]). Nevertheless, autoimmune diseases often 
require lifelong treatment, are considerably more preva-
lent among women and are among the 10 leading causes 
of mortalilty in women under 65 years. It is also interest-
ing to compare the prevalence of autoimmune diseases to, 
for example, heart disease (22%) and cancer (9%), which 
seem to have a much higher public profile [1] and research 
support with funding quoted in billions of dollars rather 
than the millions for autoimmune diseases. The incidence 
of autoimmune diseases is increasing. For example, the 
International Diabetes Atlas reported that in 2017 there 
were 10  million more adults worldwide with type I dia-
betes that in 2015, and if this trend continues, by 2045, 
67 million Europeans will be living with type I diabetes [2].
Over the last 20 years, our ability to detect and quan-
tify the antibodies involved in autoimmune diseases has 
improved, and gradually such tests are becoming incor-
porated onto high throughput platforms often in Clinical 
Blood Sciences. However, autoantibody measurements 
can lack clinical specificity and sensitivity and show high 
variation between platforms and tests, and certified refer-
ence materials are only recently available for only a small 
number of autoantibodies. The number of requests is 
increasing far beyond what would be expected for a tests 
for rare conditions and with low pretest probabilities. 
Numerical reports give no impression of the “uncertainty” 
of the result, and the enthusiasm for automated analysis 
and reporting puts the responsibility on the requesting cli-
nician to interpret the result, often without understanding 
of the limitations of the test.
This issue of Clinical Chemistry and Laboratory Medi-
cine highlights the diversity of autoimmune disease from 
organ-specific conditions to systemic multiorgan disease. 
It reminds us that there is significant overlap between 
Clinical Chemistry and Immunology and that we have 
an important role the diagnosis and management of a 
variety of autoimmune disease. We can clearly see how 
much work is being done to investigate, understand and 
improve autoantibody testing, but there is still much to 
be done to optimise the requesting, the analytical process 
and the interpretation of these complex assays.
More than 90% of cases of Addison’s disease have an 
autoimmune aetiology with antibodies to adrenal tissue 
and more specifically antibodies to 21-hydroxylase being 
markers of the disease. The symptoms of adrenal insuf-
ficiency can be subtle, but patients may also present as 
an emergency in Addisonian crisis. It is also well known 
that Addison’s is associated with other autoimmune 
 endocrinopathies, e.g. Grave’s disease, hypothyroidism 
or type I diabetes. Manso et al. [3] describe a patient with 
autoimmune hypothyroidism where the patient’s family 
history led to the finding of positive anti-adrenal anti-
bodies. Further investigation confirmed the diagnosis of 
subclinical Addison’s and treatment was started. Their 
literature review showed that only 1% of patients with 
autoimmune thyroid disease had anti-adrenal-cortex 
antibodies. Use of a more sensitive ELISA-based assay 
increased the detection of antibodies to 21-hydroxylase 
in children with autoimmune thyroid disease to approxi-
mately 4 percent, although even at this frequency, it 
would only be worth checking for anti-adrenal antibodies 
in patient with clinical features or family history. Surpris-
ingly, anti-adrenal-cortex antibodies are found in a much 
greater proportion of patients with premature ovarian 
failure and in chronic hypoparathyroidism, so screening 
for antibodies to 21-hydroxylase in such patients may be 
useful. Classically, adrenal antibodies have been detected 
by indirect immunofluorescence. This can be technically 
demanding, and the interpretation of the staining needs 
considerable training and experience. del Pilar Larosa 
et  al. [4] have reported the development of an ELISA 
for 21-hydroxylase, the enzyme, which is the important 
antigen within the adrenal cortex. They report good speci-
ficity and sensitivity for Addison’s disease so this may be 
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a better method for supporting a diagnosis of Addison’s 
than the qualitative immunofluorescence techniques.
Type I diabetes also has an autoimmune  aetiology, and 
in patients where the clinical and biochemical presentation 
is complex, antibodies to insulin, glutamic acid decarbox-
ylase (GAD), insulinoma antigen (IA2) and zinc transporter 
8 (ZnT8) may be measured to improve the diagnostic power. 
Censi et al. [5] report the case of a patient with high blood 
insulin concentrations, hypoglycaemia and a high serum 
concentration of antibodies to insulin. It is important that 
we are aware of these antibodies because they loosely bind 
to insulin, which is gradually released independent of the 
normal feedback mechanism generating hypoglycaemia. 
These circulating anti-insulin autoantibodies also have the 
capacity to interfere in analyses that may be used in the 
investigation of unexplained hypoglycaemia, e.g. insulin, 
C-peptide and proinsulin immunoassays.
There has been a dramatic improvement in the under-
standing of autoimmune mediated neuropathies over the 
last 20 years with autoantibody responses to gangliosides 
being implicated in their pathology. These conditions can 
be acute or chronic; they can affect the motor, sensory or 
autonomic nerves; and the presenting features can be var-
iable. Improved diagnosis with prompt treatment could 
prevent irreversible nerve damage and consequent dis-
ability. Klehmet et al. [6] describe a multiplex approach to 
detecting antibodies IgG and IgM antibodies to 11 ganglio-
side antigens in patients with autoimmune neuropathies, 
other neurological conditions and normal subjects. The 
IgM anti-sulphatyl, IgM anti-GM1 and IgM anti-GD1b anti-
bodies showed a higher frequency in the inflammatory 
neuropathy patients compared to patients with other neu-
rological conditions. This is early data, and the authors 
suggest that further investigation is warranted, but it does 
show the power of multiplex-type analysis in identifying 
markers for further directed investigation.
The term “phospholipid” antibodies like the term “neu-
rological” antibodies describes antibodies to a number of 
distinct antigenic targets. In both situations, the tissues 
where these antigens are expressed are throughout the 
body generating widespread symptoms. Phospholipids, 
including cardiolipin and β2 glycoprotein 1, phosphatidyl-
choline, phosphatidylethanolamine, phosphatidylserine 
and phosphatidylinositol, are an integral part of all cell 
membranes. Antibodies to these components are associ-
ated with arterial or venous thrombosis. There are well-
defined diagnostic criteria for antiphospholipid syndrome, 
but only measurements of IgG and IgM antibodies to car-
diolipin and/or β2 glycoprotein 1 are included alongside 
lupus anticoagulant (an adaptation of a clotting test). 
Antibodies to the other phospholipids have generally been 
considered to have limited diagnostic value; however, 
Zhang et  al. [7] have evaluated the clinical relevance of 
antibodies to a phosphatidylserine- prothrombin complex. 
They found increased concentrations of IgG and IgM anti-
bodies to phosphatidylserine-prothrombin complex in 
their patients with antiphospholipid syndrome, although 
in their study, cardiolipin antibodies showed the best 
clinical performance. Interestingly, antibodies to the 
phosphatidylserine-prothrombin complex were detected 
in patients with clinical features of antiphospholipid syn-
drome, but negative antibodies to the classical antigens, 
suggesting that although the majority of patients show 
cardiolipin antibodies, other antigenic specificities may 
be important in individual patients.
Antinuclear antibodies (ANAs) is a commonly 
requested autoantibody with importance in the diagno-
sis of systemic autoimmune rheumatic diseases such as 
systemic lupus erythematosus, Sjogren syndrome, etc. 
ANAs have classically been detected by a manual indirect 
immunofluorescence method, which needs good labo-
ratory skills and the ability to recognise the diverse and 
often complex patterns seen at the microscope reading 
of the slides. Samples with positive staining patterns 
have reflex testing by ELISA-based assay for antibodies to 
specific antigens. The deskilling of laboratories and the 
simple volume of requests are driving automation for ANA 
testing. Willems et al. [8] report a review of almost 10,000 
patients who were tested for ANA by indirect immunoflu-
orescence and an automated ANA “screen”. They report 
reasonable concordance and comparable receiver opera-
tor curves between the two methods. However, simply 
looking at the comparison does not tell the whole story. 
The data were also analysed by a requestor, who showed 
a significantly higher PPV for systemic autoimmune rheu-
matic diseases when testing was requested by clinicians 
specialised in systemic rheumatic disease. They con-
cluded that the performance of immunoassay and indi-
rect immunofluorescence depends on the specific disease 
being considered and that for optimum value both assay 
types are best used in combination and results interpreted 
in the context of the clinical picture.
Antibodies to the extractable nuclear antigens Ro/SSA 
and La/SSB are found in a number of systemic connective 
tissue diseases, e.g. Sjogren syndrome, systemic lupus 
erythematosus, etc. These antibodies, if present, cross 
the placenta from mum to baby as part of the active IgG 
transport. The Ro and La antigens are expressed in foetal 
cardiac tissue from the 18th to the 24th week, particularly 
on the surface of cardiac myocytes, and in a proportion of 
patients, the antibodies cause inflammation, fibrosis and 
calcification of foetal cardiac conduction tissues leading 
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to atrioventricular block. Antibodies to the p200 epitope of 
the Ro52/SSA antigen appear to have a critical pathogenic 
role the development of foetal heart block. Mattia et al. [9] 
have evaluated the performance of two “in-house” assays 
for anti-p200 antibodies in pregnant women positive for 
anti- SSA/Ro52 antibodies. They did find differences in 
assay performance, but further investigation may identify 
an analytical process for anti-p-200 antibodies that may 
help identify patients who are at a significantly increased 
risk future pregnancy being affected by foetal heart block.
Antineutrophil cytoplasmic antibodies (ANCAs) are 
autoantibodies that are mainly directed against the cyto-
plasmic antigens proteinase 3 and myeloperoxidase of 
neutrophils and the monocytes. Their presence is associ-
ated with systemic vasculitides and in particular granu-
lomatosis with polyangiitis, microscopic polyangiitis and 
Churg-Straus syndrome. Like ANAs, indirect immuno-
fluorescence and ELISA-based assay are used together to 
detect and quantify these antibodies with a similar drive 
to replace the qualitative tests with automated quanti-
tative analyses. Certified reference preparations for IgG 
anti-proteinase 3 and IgG anti-myeloperoxidase are only 
recently available and are not yet embedded in the analyti-
cal process, making comparison of results over time and 
between methods difficult. Borderline positive results, 
irrespective of the method used, present the greatest inter-
pretative challenge with limited data on their significance. 
Watad et  al. [10] present a retrospective study of ANCA 
investigations and conclude that patients with borderline-
positive IgG anti-myeloperoxidase antibodies and posi-
tive ANCA staining by indirect immunofluorescence have 
a poorer outcome in terms of their renal function than 
patients with negative ANCA staining.
Autoantibodies are complex analytes; the antigens 
that we use in the analysis vary subtly between  companies, 
and even within a company between different lots, the 
antibodies that we are trying to detect can vary between 
patients and even within a patient during the disease 
course. The demand for autoantibody testing, particularly 
for the rare autoimmune diseases, is increasing beyond 
logic, but instead of educating users and optimising 
demand, we are increasing the capacity for measurement 
with high throughput automated systems. The analytical 
speed and detection systems introduce another source of 
variation into a group of tests where robust standardisa-
tion does not exist.
The papers in this issue of Clinical Chemistry and Lab-
oratory Medicine clearly show the relevance of autoanti-
body testing in a diverse range of disease. However, none 
of the analytes described in these eight papers were meas-
ured with respect to certified reference materials; as a 
scientific community, we need to embrace standardisa-
tion (or harmonisation) for autoantibody testing. Some 
of these papers also review large amounts of data, e.g. 
14,555 ANCA results over a 10-year period [10] and 9856 
ANA results over a 2-year period [8]. We consider the 
approximate incidence and prevalence of ANCA vasculitis 
(incidence 2/100,000 and prevalence 26/100,000) and SLE 
(incidence 5/100,000 and prevalence 52/100,000), but we 
may question why so many of these tests were requested 
when the pretest probability is so low. We have two enor-
mous challenges – to ensure that test tests are requested 
appropriately and to improve the analysis and reduce the 
variability of autoantibody testing.
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